{
  "id": 6433179,
  "title": "Arcus Biosciences at Citi summit: casdatifan data loom large",
  "url": "https://urgent.news/2026/09/09/arcus-biosciences-at-citi-summit-casdatifan-data-loom-large",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-09T15:45:17.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/arcus-biosciences-at-citi-summit-casdatifan-data-loom-large-93CH-4894121"
  },
  "original_language": "en",
  "account": "On September 9, 2026, Arcus Biosciences presented its casdatifan, a HIF-2α inhibitor for clear cell renal cell carcinoma, at Citigroup's Biopharma Back to School Summit. The company highlighted promising early and mid-stage data on casdatifan, but also pointed to a key near-term risk: investors need to see if casdatifan can deliver an overall survival advantage over strong progression-free survival. Arcus claimed casdatifan has a superior pharmacokinetic profile compared to Merck's belzutifan, with dose-proportional and linear behavior that may allow deeper target engagement. They plan to release new data in October on casdatifan's late-line monotherapy, PEAK-1 second-line study, and first-line combination programs. Late-line monotherapy data shows a progression-free survival of 12-15 months, compared to belzutifan's 5.6 months in LITESPARK-005. Arcus estimates its first-line program could have a market opportunity of $4 billion or more, while the second-line program represents $1.5 billion to $2 billion. They emphasized that the October update will provide the first overall survival data for casdatifan in this setting, which could be a significant differentiator for commercialization in both the U.S. and internationally.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}